(C, E) in the culture SNs by ELISA. The control groups were administered with PBS, BCG and sIM. Data are shown as mean 6 SEM and representative of two experiments, n = 3 animals per group. ‘*’ and ‘**’ indicate p,0.05 and p,0.01 respectively. (TIF) Figure S3 sIM-1.6.a does not increase Th2 response. Mice were vaccinated as mentioned in Figure S1. Lymphocytes Pooled from spleens and lymph nodes (A) and lungs (B) were stimulated in vitro with PPD, STCF-H37Rv and IMC (50 mg/ml). Secretion of IL-4 and IL-5 was monitored in the culture SNs. The control groups were administered with PBS, BCG and sIM. Data are shown as mean 6 SEM and representative of two experiments, n = 3 animals per group. (TIF) Figure S4 sIM-7.15 and BCG-1.6.a failed to show any protection. sIM-7.15 and BCG-1.6.a vaccinated mice were rested for 240 days before aerosol challenge. After 35 days, animals were sacrificed; mycobacterial load was enumerated by CFU plating. Control groups were immunized with syngeneic uninfected macrophages (sMac), BCG and cytokines alone (1.6.a and 7.15). Data are represented as mean 6 SEM of log10 CFU (n = 4–5 animals/group) of two independent experiments. (TIF) Figure S5 Immunization with xIM-1.6.a also elicits robust immune response against STCF-H37Rv. Mice were vaccinated with xIM-1.6.a and xIM. After 240 days, they were aerosol challenged with M. tb and 35 days later were sacrificed. Lymphocytes Pooled from spleens and lymph nodes (A, B, C) and lungs (D, E) were stimulated in vitro with STCF-H37Rv (50 mg/ml). T cell proliferation was monitored by 3H-thymidine incorporation (A); release of IFN-c (B, D) and IL-2 (C, E) in the culture SNs by ELISA. Data are shown as mean 6 SEM and representative of two experiments, n = 3 animals per group. ‘*’ and ‘**’ indicate p,0.05 and p,0.01 respectively. (TIF) References 1. WHO (1992) Expanded program for immunization: program report. World Health Organization. 2. WHO (2009) Tuberculosis fact sheet number 104, World Health Organization. 3. WHO (1998) Global tuberculosis control. World Health Organization. 4. Andersen P, Smedegaard B (2000) CD4(+) T-cell subsets that mediate immunological memory to Mycobacterium tuberculosis infection in mice. Infect Immun 68: 621–629. 5. Sharma N, Agrewala JN (2004) Potent role of vaccines prepared from macrophages infected with live bacteria in protection against Mycobacterium tuberculosis and Salmonella typhimurium infections. J Infect Dis 190: 107–114. 6. Orme IM, McMurray DN, Belisle JT (2001) Tuberculosis vaccine development: recent progress. Trends Microbiol 9: 115–118. 7. Kaufmann SH, Baumann S, Nasser Eddine A (2006) Exploiting immunology and molecular genetics for rational vaccine design against tuberculosis. Int J Tuberc Lung Dis 10: 1068–1079. 8. Orme IM (2005) Current progress in tuberculosis vaccine development. Vaccine 23: 2105–2108. 9. Palucka AK, Ueno H, Fay JW, Banchereau J (2007) Taming cancer by inducing immunity via dendritic cells. Immunol Rev 220: 129–150. 10. Moll H (2003) Dendritic cells as a tool to combat infectious diseases. Immunol Lett 85: 153–157. 11. Ueno H, Schmitt N, Klechevsky E, Pedroza-Gonzalez A, Matsui T, et al. (2010) Harnessing human dendritic cell subsets for medicine. Immunol Rev 234: 199–212. 12. Dooms H, Abbas AK (2006) Control of CD4+ T-cell memory by cytokines and costimulators. Immunol Rev 211: 23–38. 13. Schluns KS, Lefrancois L (2003) Cytokine control of memory T-cell development and survival. Nat Rev Immunol 3: 269–279. 14. Haynes L, Eaton SM, Burns EM, Rincon M, Swain SL (2004) Inflammatory cytokines overcome age-related defects in CD4 T cell responses in vivo. J Immunol 172: 5194–5199. Infected Macrophages as Vaccine Figure S6 xIM-1.6.a does not augment Th2 response. Mice were vaccinated as mentioned in Figure S5. Lymphocytes pooled from spleens and lymph nodes (A) and lungs (B) were stimulated in vitro with PPD and STCF-H37Rv (50 mg/ml). Secretion of IL-4 and IL-5 was estimated in the culture SNs. Data are shown as mean 6 SEM and representative of two experiments, n = 3 animals per group. (TIF) Figure S7 sIM-1.6.a and xIM-1.6.a provides compara- ble protection against M. tb. Mice were vaccinated with sIM- 1.6.a and xIM-1.6.a and rested for 240 days before aerosol challenge with M. tb. After 35 days, mice were sacrificed and mycobacterial load was enumerated by CFU plating of diluted lung homogenates. Control groups were inoculated with PBS and BCG. Data are represented as mean 6 SEM of log10 CFU (n = 4– 5 animals/group) of two independent experiments. ‘ns’, ‘*’, ‘**’and ‘***’ indicate non-significant, p,0.05, p,0.01 and p,0.001 respectively. (TIF) Acknowledgments We are grateful to Dr. V. M. Katoch, Director, NJIL&OMD, Agra, India for providing mycobacterial strains (M. tb H37Rv, M. bovis BCG) and BSL- 3 facility for conducting experiments; Dr. B.N. Dutta, Ex-Professor, Post graduate Institute of Medical Education and Research, Chandigarh, India for histopathological analysis. We thank the Council for Scientific and Industrial Research, India (VS, SJ) and Department of Biotechnology, India (UG) for fellowship. Author Contributions Conceived and designed the experiments: JNA VS. Performed the experiments: VS SJ UG PP PG. Analyzed the data: JNA VS. Contributed reagents/materials/analysis tools: UDG. Wrote the paper: JNA VS. 15. Pape KA, Khoruts A, Mondino A, Jenkins MK (1997) Inflammatory cytokines enhance the in vivo clonal expansion and differentiation of antigen-activated CD4+ T cells. J Immunol 159: 591–598. 16. Melchionda F, Fry TJ, Milliron MJ, McKirdy MA, Tagaya Y, et al. (2005) Adjuvant IL-7 or IL-15 overcomes immunodominance and improves survival of the CD8+ memory cell pool. J Clin Invest 115: 1177–1187. 17. Rochman Y, Spolski R, Leonard WJ (2009) New insights into the regulation of T cells by gamma(c) family cytokines. Nat Rev Immunol 9: 480–490. 18. Orme IM (2006) Preclinical testing of new vaccines for tuberculosis: a comprehensive review. Vaccine 24: 2–19. 19. Singh V, Gowthaman U, Jain S, Parihar P, Banskar S, et al. (2010) Co- administration of IL-7 and IL-15 with BCG mount enduring T cell memory response against M. tuberculosis. J Infect Dis 202: 480–489. 20. Jung YJ, Ryan L, LaCourse R, North RJ (2005) Properties and protective value of the secondary versus primary T helper type 1 response to airborne Mycobacterium tuberculosis infection in mice. J Exp Med 201: 1915–1924. 21. Stevens TL, Bossie A, Sanders VM, Fernandez-Botran R, Coffman RL, et al. (1988) Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells. Nature 334: 255–258. 22. Wolf AJ, Desvignes L, Linas B, Banaiee N, Tamura T, et al. (2008) Initiation of the adaptive immune response to Mycobacterium tuberculosis depends on antigen production in the local lymph node, not the lungs. J Exp Med 205: 105–115. 23. Swain SL, Agrewala JN, Brown DM, Jelley-Gibbs DM, Golech S, et al. (2006) CD4+ T-cell memory: generation and multi-faceted roles for CD4+ T cells in protective immunity to influenza. Immunol Rev 211: 8–22. 24. Agrewala JN, Brown DM, Lepak NM, Duso D, Huston G, et al. (2007) Unique ability of activated CD4+ T cells but not rested effectors to migrate to non- lymphoid sites in the absence of inflammation. J Biol Chem 282: 6106–6115. 25. Agrewala JN, Suvas S, Singh V, Vohra H (2003) Delivery of antigen in allogeneic cells preferentially generates CD(4+) Th1 cells. Clin Exp Immunol 134: 13–22. PLoS ONE | www.plosone.org 11 January 2011 | Volume 6 | Issue 1 | e16097